Scientists have identified a driver of drug resistance in breast, ovarian and prostate cancers that may help doctors predict which patients will become resistant to a class of drugs frequently used to treat BRCA 1/2-deficient tumors.
* The researchers studied more than 600,000 genetic variants in the genome of 166 patients treated with the chemotherapy drug capecitabine * Before undergoing treatment, the patients carrying the risk alleles for the hand-foot syndrome had low levels of two proteins that are key to the effective functioning of the skin barrier * The finding may help classify patients according to their genetic risk for developing this side effect of some cancer treatments
One in seven black women with breast cancer had delays in starting treatment, and black women also had extended duration of treatment, according to a study led by UNC Lineberger Comprehensive Cancer Center researchers.
New research suggests that Black women experience longer waits for treatment initiation than white women after a breast cancer diagnosis, and their duration of treatment is prolonged. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society (ACS).
Lugano, Switzerland, 20 September 2020 - Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, according to results from a study at ESMO 2020.
A dangerous protein named SNAI2 helps cancers metastasize and shields cancer from both the immune system and chemotherapy. Worse, SNAI2 is in a family of proteins that are notoriously hard to fight with drugs. But now Princeton University's Yibin Kang and his colleagues have found a way to use the cell's recycling system to control SNAI2, providing a new possibility for treatments.
Breast cancer patients whose disease has spread to their brains fare better if their metastases are picked up before they begin to cause symptoms, according to a study presented at the 12th European Breast Cancer Conference.
Researchers studying the activity of gut bacteria in breast cancer patients have found a possible link with how well their chemotherapy works.
Researchers investigated differences in quality of life and other outcomes (including physical functioning, body image, sexual health, anxiety and depressive symptoms) by type of breast cancer surgery (such as mastectomy or breast conserving surgery) in women 40 and younger.
A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal.